Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02064907 · ClinicalTrials.gov registry record · Phase 1
Bioavailability, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets in Healthy Participants
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT02064907 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 52 participants.
The verdict
NCT02064907, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the pharmacokinetics (PK) and Pharmacodynamics (PD) of dexlansoprazole delayed-release orally disintegrating (OD) tablets administered on the tongue and swallowed without water.
Interventions
- DRUG Dexlansoprazole Delayed Release Orally Disintegrating Tablets
- DRUG Dexlansoprazole Delayed Release Capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02064907
The ClinicalTrials.gov registry entry for NCT02064907 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dexlansoprazole Delayed Release Orally Disintegrating Tablets is the first listed.
NCT02064907 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02064907 about?
NCT02064907 is a clinical study titled "Bioavailability, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets in Healthy Participants". The purpose of this study is to assess the pharmacokinetics (PK) and Pharmacodynamics (PD) of dexlansoprazole delayed-release orally disintegrating (OD) tablets administered on the tongue and swallowed without water.
What is the current status of trial NCT02064907?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2014-02. Estimated completion is 2014-04.
What interventions are being tested in trial NCT02064907?
The interventions under investigation include: Dexlansoprazole Delayed Release Orally Disintegrating Tablets (DRUG), Dexlansoprazole Delayed Release Capsules (DRUG).
Who is sponsoring clinical trial NCT02064907?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.